Engineered therapeutic antibodies with improved effector functions
- 11 August 2009
- journal article
- review article
- Published by Wiley in Cancer Science
- Vol. 100 (9), 1566-1572
- https://doi.org/10.1111/j.1349-7006.2009.01222.x
Abstract
In the past decade, more than 20 therapeutic antibodies have been approved for clinical use and many others are now at the clinical and preclinical stage of development. Fragment crystallizable (Fc)-dependent antibody functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and a long half-life, have been suggested as important clinical mechanisms of therapeutic antibodies. These functions are primarily triggered through direct interaction of the Fc domain with its corresponding receptors: FcgammaRIIIa for ADCC, C1q for CDC, and neonatal Fc receptor for prolongation of the clearance rate. However, current antibody therapy still faces the critical issues of insufficient efficacy and the high cost of the therapeutic agents. A possible solution to these issues could be to engineer antibody molecules to enhance their antitumor activity, leading to improved therapeutic outcomes and reduced doses. Here, we review advanced Fc engineering approaches for the enhancement of effector functions, some of which are now ready for evaluation of their effectiveness in clinical trials.Keywords
This publication has 76 references indexed in Scilit:
- Anti–Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today?The Oncologist, 2009
- First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trialBlood, 2008
- The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumabEuropean Journal Of Cancer, 2008
- Monoclonal Antibodies in Cancer Therapy: 25 Years of ProgressJournal of Clinical Oncology, 2008
- Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximabBlood, 2006
- The therapeutic antibodies market to 2008European Journal of Pharmaceutics and Biopharmaceutics, 2005
- Crystallographic structure of an intact IgG1 monoclonal antibody 1 1Edited by I. A. WilsonJournal of Molecular Biology, 1998
- Increasing the serum persistence of an IgG fragment by random mutagenesisNature Biotechnology, 1997
- Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in miceNature Genetics, 1997
- Replacing the complementarity-determining regions in a human antibody with those from a mouseNature, 1986